title: Treatment of humoral rejection with rituximab.
abstract: Humoral vascular rejection is a B cell-mediated production of immunoglobulin G antibody against the transplanted organ. Available treatments of vascular rejection offer limited success, and chronic manifestations of vascular rejection require retransplantation. On the basis of the mechanism of action of rituximab, we successfully treated 1 patient with vascular rejection refractory to plasmapheresis with this drug without major toxicity.
authors.affiliation: Division of Cardiothoracic Surgery, University of Tennessee, Memphis, USA.
authors.forename: H Edward
authors.initials: HE
authors.lastname: Garrett
authors.forename: Kenneth
authors.initials: K
authors.lastname: Groshart
authors.forename: Denise
authors.initials: D
authors.lastname: Duvall-Seaman
authors.forename: Deena
authors.initials: D
authors.lastname: Combs
authors.forename: Rita
authors.initials: R
authors.lastname: Suggs
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000917:Antibody Formation; D001402:B-Lymphocytes / Q000276:immunology*; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy*; D016027:Heart Transplantation / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis; D008875:Middle Aged; D010956:Plasmapheresis; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007074:Immunoglobulin G; D000069283:Rituximab